Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance

Why It Matters

The turnaround to positive cash flow and accelerated revenue growth signal Harrow’s emerging scale in ophthalmic therapeutics, positioning it for sustained investor confidence and market expansion.

Key Takeaways

• Revenue up 36% YoY to $272.3M.
• Q4 record revenue $89.1M, 33% increase.
• Adjusted EBITDA reaches $61.9M, up from $40.3M.
• Operating cash flow flips to $43.9M positive.
• 2026 guidance targets $350‑$365M revenue, $80‑$100M EBITDA.

Pulse Analysis

Harrow’s 2025 financial results underscore a rapid ascent in the ophthalmic disease‑management market. By delivering a 36% revenue surge to $272.3 million, the firm leveraged the commercial momentum of its flagship products—VEVYE®, IHEEZO®, and TRIESENCE®—which are transitioning from early‑stage launches to broader adoption. This top‑line acceleration, coupled with a stable 79% gross margin, reflects both effective pricing power and efficient cost structures, reinforcing Harrow’s competitive foothold against larger eye‑care incumbents.

Beyond revenue, Harrow demonstrated meaningful operational leverage. Adjusted EBITDA rose to $61.9 million, and operating cash flow swung from a $22 million outflow in 2024 to a $43.9 million inflow, bolstering the balance sheet to $72.9 million in cash. The improved cash generation reduces reliance on external financing and provides flexibility for strategic acquisitions, such as the Melt Pharmaceuticals integration, while supporting the planned expansion of sales teams and pipeline development.

Looking ahead, the company’s 2026 guidance—$350‑$365 million in revenue and $80‑$100 million Adjusted EBITDA—signals confidence in scaling its commercial platform. Upcoming launches like G‑MELT™ and YOCHIL™, alongside a next‑generation TRIESENCE syringe, aim to diversify the product mix and capture larger market segments. While execution risk remains, especially around regulatory approvals and competitive pressures, Harrow’s trajectory positions it as a potential cash‑generating powerhouse in the eye‑care sector by 2027 and beyond.